Blog | Page 12 of 27

Oncotarget News

Figure 2: Rapamycin prevents cancer by slowing tumor progression (hypothetical schema).

Cancer Prevention With Rapamycin

April 17, 2023

long-term treatment with rapamycin slows down aging, a major risk factor for cancer [...]”BUFFALO, NY- April 17, 2023 – A new research perspective was published in Oncotarget's Volume 14 on April... read more

Figure 1: Pre- and post-treatment scans confirmed partial responder. (From a phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850.”)

Oncotarget

Riluzole and Sorafenib in Patients With Advanced Solid Tumors: A Phase I Trial

April 12, 2023

Our phase I study determined the tolerable dose of this combination and investigated its biologic effects.” BUFFALO, NY- April 12, 2023 – A new research paper was published in Oncotarget's... read more

Figure 2: Active pharmacological intervention trials in TNBC.

Oncotarget

Crosstalk Between Triple Negative Breast Cancer and Microenvironment

April 10, 2023

the study of immunotherapy for treating triple negative breast cancer might still be at its early stages of development but is full of future promise.” BUFFALO, NY- April 10,... read more

Oncotarget

Cancer-Associated Fibroblasts: Challenges and Opportunities

April 5, 2023

Beyond detection of cancer, CAFs are being actively pursued as targets for therapy.” BUFFALO, NY- April 5, 2023 – A new editorial perspective was published in Oncotarget's Volume 14 on... read more

Figure 1: The molecular mechanism(s) of how Wnt5a signaling could (i) induce ROR1 and cortactin association, tyrosine phosphorylation of cortactin, and activation of RhoA, (ii) enhance F-actin polymerization, and (iii) subsequently promote migration or metastasis of cancer cells.

Oncotarget

Impact of Cortactin in Cancer Progression

April 4, 2023

Cortactin (also known as EMS1 or CTTN) is expressed broadly in a variety of cancers [...]” BUFFALO, NY- April 4, 2023 – A new editorial paper was published in Oncotarget's Volume... read more

Oncotarget

Oncotarget at AACR Annual Meeting 2023

April 4, 2023

Impact Journals (Oncotarget's publisher) is proud to participate at the American Association for Cancer Research (AACR) Annual Meeting 2023, which convenes April 14-19 in Orlando, Florida.BUFFALO, NY-April... read more

Figure 7: Effects of TGF-β receptor inhibitor EW7197 with and without TGF-β1 for LSR, TRIC, OCLN, and CLDN-2 in human lung epithelial cells (HLE) cells with and without 10% FBS.

Oncotarget

Downregulation of Angulin-1/LSR Induces Malignancy in Lung Adenocarcinoma

March 29, 2023

In the present study, we found that downregulation of angulin-1/LSR induced malignancy via upregulation of EGF-dependent CLDN-2 and TGF-β-dependent cell metabolism in human lung adenocarcinoma.” BUFFALO, NY-... read more

Figure 5: NSL-YHJ-2-27 suppresses cancer cell migration and invasion.

Oncotarget

Oncotarget | Polyisoprenylated Cysteinyl Amide Inhibitors Deplete G-Proteins in Cancer Cells

March 28, 2023

mutations in G-proteins have been associated in the progress of several cancers [...]” BUFFALO, NY- March 28, 2023 – A new research paper was published in Oncotarget's Volume 14 on March... read more

Figure 6: Overexpression of GPC1 increases proliferation of T24 cells.

Oncotarget

Oncotarget | Attenuation of Cancer Proliferation by Suppression of Glypican-1

March 22, 2023

This study was designed to increase the knowledge on the potential of GPCs and in particular GPC1 as a biomarker in cancer diagnosis and prognosis.” BUFFALO, NY- March 22,... read more

Oncotarget

Oncotarget | Unlocking the Potential of Molecular-Driven Stratification of Osteosarcoma

March 20, 2023

We are very enthusiastic about these initiatives and the recent rate of discoveries in OSA, and hopeful that they will bring actionable targets for OSA.” BUFFALO, NY- March 20,... read more